Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC versus LODINE.
DICLOFENAC vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Clinical Note
moderateDiclofenac + Gatifloxacin
"Diclofenac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiclofenac + Rosoxacin
"Diclofenac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiclofenac + Levofloxacin
"Diclofenac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiclofenac + Trovafloxacin
"Diclofenac may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category D/X
Category C
NSAID
NSAID